Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges

Vandana Singh
2 min read
0
In this article:

  • HC Wainwright initiated coverage on SQZ Biotechnologies Company (NYSE: SQZ) with a Buy rating and a price target of $10.

  • SQZ is focused on developing novel therapeutic cell therapy platforms centering around the company's Cell Squeeze technology.

  • The analyst writes that there is significant potential for the Cell Squeeze technology for many disease areas and oncology indications.

  • The likely next target in oncology is KRAS G12D and/or G12V mutations, given positive preclinical results which showed antigen-specific CD8+ T cells which were more effective than active control.

  • The company's pipeline currently consists of four cell therapy platforms.

    • The Antigen Presenting Cell (APC) platform is the furthest along in development, with initial proof of concept data achieved in collaboration with Roche Holdings AG (OTC: RHHBY), which adds credibility to the technology.

    • The enhanced APC (eAPC) platform improves on the APC platform.

    • The activating antigen carrier (AAC) platform consists of engineered red blood cells (RBCs) with the Cell Squeeze technology to comprise tumor-specific antigens.

    • The tolerizing antigen carrier (TAC) platform induces antigen-specific immune tolerance in vivo utilizing a similar approach as the AAC platform; the initial indication is celiac disease (IND expected 1H23).

  • The APC program will have updated data, and the eAPC and AAC programs will have initial data in 4Q22, creating multiple potential significant catalysts before year-end.

  • Price Action: SQZ shares are up 6.74% at $3.01 on the last check Thursday.

Latest Ratings for SQZ

Date

Firm

Action

From

To

Jan 2021

Evercore ISI Group

Initiates Coverage On

Outperform

Nov 2020

B of A Securities

Initiates Coverage On

Buy

Nov 2020

BTIG

Initiates Coverage On

Buy

View More Analyst Ratings for SQZ

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories